Technical Analysis for NEXI - NexImmune, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | -1.01% | |
| Bollinger Band Squeeze | Range Contraction | -1.01% | |
| Outside Day | Range Expansion | -1.01% | |
| Gapped Down | Weakness | -1.01% | |
| Bollinger Band Squeeze | Range Contraction | 0.88% | |
| NR7 | Range Contraction | 0.88% | |
| NR7-2 | Range Contraction | 0.88% | |
| Narrow Range Bar | Range Contraction | 0.88% | |
| Earnings Movers | Other | 0.88% | |
| Gapped Up | Strength | 0.88% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 3 hours ago |
| Fell Below 10 DMA | about 3 hours ago |
| Gap Down Partially Closed | about 3 hours ago |
| Gap Down Closed | about 3 hours ago |
| Reversed from Down | about 3 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.6949 |
| 52 Week Low | 1.2501 |
| Average Volume | 51,869 |
| 200-Day Moving Average | 5.25 |
| 50-Day Moving Average | 4.43 |
| 20-Day Moving Average | 3.40 |
| 10-Day Moving Average | 3.43 |
| Average True Range | 0.34 |
| RSI (14) | 43.50 |
| ADX | 14.98 |
| +DI | 18.65 |
| -DI | 17.88 |
| Chandelier Exit (Long, 3 ATRs) | 2.86 |
| Chandelier Exit (Short, 3 ATRs) | 4.04 |
| Upper Bollinger Bands | 3.66 |
| Lower Bollinger Band | 3.14 |
| Percent B (%b) | 0.62 |
| BandWidth | 15.51 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.37 |
| MACD Histogram | 0.1066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.84 | ||||
| Resistance 3 (R3) | 3.83 | 3.69 | 3.77 | ||
| Resistance 2 (R2) | 3.69 | 3.60 | 3.70 | 3.75 | |
| Resistance 1 (R1) | 3.58 | 3.54 | 3.63 | 3.59 | 3.73 |
| Pivot Point | 3.44 | 3.44 | 3.47 | 3.45 | 3.44 |
| Support 1 (S1) | 3.33 | 3.35 | 3.39 | 3.34 | 3.20 |
| Support 2 (S2) | 3.20 | 3.29 | 3.20 | 3.18 | |
| Support 3 (S3) | 3.08 | 3.20 | 3.16 | ||
| Support 4 (S4) | 3.09 |
